CANDER, S. Et Al. 2017. Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients. METABOLIC SYNDROME AND RELATED DISORDERS , vol.15, no.5 , 220-225.

CANDER, S., ÖZ GÜL, Ö., Dizdar, O. S., Koca, N., Aydin, T., SARANDÖL, E., ... ERSOY, C.(2017). Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients. METABOLIC SYNDROME AND RELATED DISORDERS , vol.15, no.5, 220-225.

CANDER, SONER Et Al. "Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients," METABOLIC SYNDROME AND RELATED DISORDERS , vol.15, no.5, 220-225, 2017

CANDER, SONER Et Al. "Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients." METABOLIC SYNDROME AND RELATED DISORDERS , vol.15, no.5, pp.220-225, 2017

CANDER, S. Et Al. (2017) . "Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients." METABOLIC SYNDROME AND RELATED DISORDERS , vol.15, no.5, pp.220-225.

@article{article, author={SONER CANDER Et Al. }, title={Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients}, journal={METABOLIC SYNDROME AND RELATED DISORDERS}, year=2017, pages={220-225} }